CGTX - NASDAQ
Cognition Therapeutics, Inc.
$1.42
+14%Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
At a Glance
Live SnapshotCognition Therapeutics, Inc. Management Team
Ms. Lisa Ricciardi
Chief Executive Officer, President & Director
Compensation
$951,736
Mr. John Brendan Doyle
Chief Financial Officer
Compensation
$619,940
Dr. Anthony O. Caggiano M.D., Ph.D.
Chief Medical Officer and Head of R&D
Compensation
$676,372
Mr. Bobby Horn
Corporate Controller
Ms. Anita Cornet
Head of Quality
Dr. Steven A. Weissman Ph.D.
Vice President & Head of CMC
Cognition Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $32K and sold $42K worth of CGTX shares, resulting in $10K of net selling activity.
3 Months
29.2K
32.49K
0
0.00
+32K
+$32K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
7.7K
6.49K
-6K
-$6K
9-12 Months
0
0.00
53.0K
35.55K
-36K
-$36K
Top Buyers
Doyle John Brendan
Officer: Chief Financial Officer
$11K
Caggiano Anthony
Officer: Chief Medical Officer
$11K
Ricciardi Lisa
Director, Officer: Ceo & President
$10K
Top Sellers
Ricciardi Lisa
Director, Officer: Ceo & President
$16K
Caggiano Anthony
Officer: Chief Medical Officer
$14K
Fletcher Aaron G.L.
Director, 10 Percent Owner:
$6K
Doyle John Brendan
Officer: Chief Financial Officer
$6K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $10K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
SEC Filings
CGTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 18, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 24, 2023 | June 09, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 25, 2022 | June 10, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.